Table 1.
Baseline characteristics of patients.
| Radiation Group (22) | Surgery Group (32) | p Value | |
|---|---|---|---|
| Mean age (years) | 60.8 ± 15.9 | 59.6 ± 14.2 | 0.781 |
| Male | 10 (32.3%) | 13 (41.9%) | 0.835 |
| Primary tumors | 0.614 | ||
| Breast | 27.3% | 21.9% | |
| Lung | 18.2% | 15.6% | |
| Multiple Myeloma | 18.2% | 9.4% | |
| Prostate | 4.5% | 9.4% | |
| Hepatic | 4.5% | 6.3% | |
| Melanoma | 9.1% | 3.1% | |
| Bladder | 4.5% | 3.1% | |
| Other | 13.7% | 31.2% | |
| Time from tumor diagnosis to AMSCC (y) | 6.9 ± 5.9 | 2.5 ± 5 | 0.005 |
| Number of spinal metastases | 2.9 ± 1.4 | 2.3 ± 1.3 | 0.1546 |
| Osseous metastases other than spine | 1.4 ± 1.4 | 0.5 ± 0.7 | 0.004 |
| Soft tissue metastases | 1.3 ± 1.1 | 0.9 ± 1.5 | 0.378 |
| Average initial Frankel score | C | C | 0.4 |
| Average initial ASIA score | 83.7 ± 17.1 | 75.6 ± 19.5 | 0.12 |
| Ambulatory at AMSCC presentation | 9 (40.9%) | 10 (31.3%) | 0.721 |
| Continent at AMSCC presentation | 10 (45.5%) | 17 (53.1%) | 0.693 |
| Initial Karnofsky score | 51.8 ± 24.8 | 46.3 ± 14.8 | 0.306 |
| Average Karnofsky score post-treatment | 46.8 ± 20.1 | 57.5 ± 21.1 | 0.068 |
| Tokuhashi score | 6.5 ± 2.3 | 7.8 ± 2.3 | 0.053 |
| Tomita score | 6 ± 1.9 | 4.9 ± 2.1 | 0.04 |
| Average time to death (months) | 6.4 ± 12.8 | 9.9 ± 14 | 0.347 |
| Death within 30 days | 7 (31.8%) | 2 (6.3%) | 0.04 |
| Death within six months | 17 (77.3%) | 16 (50.0%) | 0.11 |